What is Rilutek (riluzole)?
Rilutek (riluzole) is a glutamate release inhibitor indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS)1,2,3.
How does Rilutek (riluzole) work?
It is still not clear how ALS develops, however it seems that the neurotransmitter glutamate plays a role in cell death. Although the exact mode of action is unclear, Rilutek (riluzole) is thought to inhibit the release of glutamate1.
Rilutek (riluzole) aims to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS). There is no evidence that it has a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms1.
Where has Rilutek (riluzole) been approved?
Rilutek (riluzole) was approved for the treatment of patients with ALS by:
Food and Drug Administration (FDA), USA, December 12, 1995
European Medical Agency (EMA), European Union, June 10, 1996
Therapeutic Goods Administration (TGA), Australia, May 3, 2002
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
How is Rilutek (riluzole) taken?
The standard dosage is1,2,3:
Complete information about Rilutek (riluzole) dosage and administration can be found in the official prescribing information listed in our resources section1,2,3.
Note: Please consult with your treating doctor for personalised dosing.
Are there any known side effects or adverse reactions of Rilutek (riluzole)?
Common adverse reactions
The most common adverse reactions listed in the prescribing information include1:
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include1,2,3:
Use in specific populations
Rilutek (riluzole) can be fatal for a fetus, it is advised to avoid pregnancies and breastfeeding.
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information1,2,3.